Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Alcon nasal spray ‘brings quick relief’

Alcon nasal spray ‘brings quick relief’

17th April 2008

A newly-approved allergy spray for patients 12 years of age and above offers rapid relief, its manufacturer Alcon has claimed.

Patanase (olopatadine hydrochloride) nasal spray was approved following the encouraging results from multiple two-week, randomised, double-blind clinical trials looking at safety, efficacy and speed of action.

Patients known to suffer from seasonal allergic rhinitis were exposed to high levels of pollen, after which wither Patanase or a placebo nasal spray was administered.

The US Food and Drug Administration’s clearance of the nasal spray for prescriptions from May this year is good news for people wanting a fast-acting nasal spray to relieve their symptoms, said senior vice president of global markets and chief marketing officer Kevin Buehler.

“We are excited to enter the nasal market and are confident that this new addition will continue to grow our topical allergy franchise,” he added.

A quarter of Alcon’s shares were recently bought from Nestle by Novartis for approximately $11 billion (5.53 billion pounds) with an agreement that Novartis could go on to buy Nestle’s remaining shares at a future date.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.